Ty1

An alpaca-derived SARS-CoV-2 RBD-specific nanobody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Ty1 is an alpaca-derived single domain antibody, which strongly binds to the SARS-CoV-2 spike protein RBD (Hanke et al., 2020).

Link	Tested on	Impact factor	Notes	Publication date
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction Spike protein In vitro Antibody	HEK293T cells expressing ACE2; Vero E6 cells	12.12	The alpaca-derived single domain antibody strongly binds to the SARS-CoV-2 spike protein RBD, thus inhibiting its interaction with the human ACE2. Ty1 neutralizes SARS-CoV-2 pseudotyped viruses and protects cells from infection in vitro.	Sep/04/2020
Picomolar SARS-CoV-2 Neutralization Using Multi-Arm PEG Nanobody Constructs In vitro	Vero E6 cells	4.08	Using sortase and click chemistry, bi- and tetravalent constructs of Ty1 nanobodies were prepared. The increased valency enhanced SARS-CoV-2 neutralization in vitro with 4-arm PEG Ty1 tetramer having IC50 in the low picomolar range in Vero E6 cells.	Dec/11/2020

Link	Publication date
Unbinding of hACE2 and inhibitors from the receptor binding domain of SARS-CoV-2 spike protein.	Jul/23/2020
SARS-CoV-2 Delta Variant Decreases Nanobody Binding and ACE2 Blocking Effectivity	Apr/19/2020
Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein	Sep/28/2021